More key appointments for the Australia China Technology Incubator with the former CEOs of Medicines Australia and AusBiotech joining its advisory board.
Glenn Cross, who recently departed AusBiotech after around 13 years with the organisation, including two as its CEO, has been appointed to the advisory board of the organisation established to support Australian companies establish and expand in the China market.
The advisory board also includes Dr Brendan Shaw, who served Medicines Australia for a decade, including four as its CEO.
The advisory board has been established to provide ACTI with greater strategic direction, broadening its industry connections.
ACTI’s incubation program is jointly delivered in Australia and China. During the first phase, the Shanghai-based mentoring and investment team will provide intensive training and mentoring programs in Australia, equipping companies with a tailor-made China entry strategy and business plan.
ACTI will hold a Bootcamp in Melbourne in late October. The two-day workshop will include sessions on developing a market entry strategy; successful partnering approaches; regulatory pathways; distribution and marketing; market risks; common pitfalls; and, key success factors for Australian healthcare products, technologies and services into China
Companies identified as being ‘China Ready’ will progress to its dedicated business incubation space in Shanghai, where they will be co-located with Chinese high-tech companies and supported by a business incubation team that is currently assisting more than 100 companie